Academy

Claire Harrison, MD - Disease Modification in Myelofibrosis: Are We There Yet and What is Next?

David Sallman, MD - TP53 Myeloid Neoplasms

Zhuoer Xie, MD - Update on CHIP/CCUS

Danielle Hammond, MD - Clonal Hematopoiesis and MPN

Panel Discussion I

Sanam Loghavi, MD - WHO/ICC Chronic Myeloid Neoplasms Harmonization

Amy DeZern, MD - State of the Art MDS Risk Assessment

Andrew Kuykendall, MD - State of the Art MPN Risk Assessment

Panel Discussion II

Daniel J. DeAngelo, MD - Update on Systemic Mastocytosis

Pankit Vachhani, MD - Update on Epidemiology and Outcomes of MPNs

Raajit K. Rampal, MD - Moving Towards Disease Modification in Polycythemia Vera

Naveen Pemmaraju, MD - Hepcidin Mimetics and Inducers in Polycythemia Vera

Abdulraheem Yacoub, MD - Updates in Essential Thrombocythemia: Where is the Field Headed?

Panel Discussion

Angela Fleischman, MD - Cytopenic MF: Biologic Insights and Clinical Considerations

Stephen Oh, MD - Management of Anemia in MF: Current and Emerging Options

Ruben Mesa, MD - The Odyssey of JAK Inhibitors for the Treatment of MF

Prithviraj Bose, MD - Novel Small Molecules and JAK Inhibitor-based Combos for MF

Jeanne Palmer, MD - Targeting Driver Mutations Better: Novel JAK Inhibitors and Mutant CALR Antibodies

Panel Discussion

Hannah Goulart, MD - Debate: Clinical Trial Endpoints & Outcomes in MF: Time for a Change or Keep Status Quo?: Yes: It’s Time for New Endpoints and Outcomes in MF Clinical Trials Beyond Spleen & Symptoms EFS, PFS, OS

Sankalp Arora, MD - Debate: Clinical Trial Endpoints & Outcomes in MF: Time for a Change or Keep Status Quo?: No: Let’s keep Spleen & Symptoms and Current Criteria for MF Response

Q&A Discussion I

Mahesh Swaminathan, MD - Debate: Frontline MF: Debating Combination Therapy vs Staying with Monotherapy: Yes: Frontline Combos for MF Are The Future because Two Drugs Are Better than One

Fadi Haddad, MD - Debate: Frontline MF: Debating Combination Therapy vs Staying with Monotherapy: No: Let’s Stay with JAKi Monotherapy for Frontline MF

Q&A Discussion II

Guillermo Garcia Manero, MD - Erythroid Maturating Agents for Management of Anemia in MDS

Amer Zeidan, MD - Telomerase Inhibitors for Treatment of MDS

Yazan Madanat, MD - Investigational Therapies in Lower-risk MDS

Uma Borate, MD - Investigational Therapies for Higher-risk MDS

Rami Komrokji, MD - IDH Mutated MDS

Panel Discussion